Vanqua Bio stock

Vanqua Bio Stock

HealthTech
Founded: 2019Funding to Date: $149Mhttps://www.vanquabio.com

Vanqua Bio is a biopharmaceutical company dedicated to creating innovative treatments for neurodegenerative diseases. The company specializes in discovering small-molecule activators of glucocerebrosidase and developing advanced programs aimed at the innate immune system, which can hasten the progression of various neurological conditions. This enables healthcare providers to improve patient outcomes with cutting-edge treatments for a range of disorders.

Investors Include:

The Silverstein Foundation for Parkinson's with GBA, Omega Funds, Casdin Capital, Surveyor Capital, Avoro Capital, Osage University Partners, Eli Lilly and Company, SymBiosis Capital Management, Pontifax Venture Capital, Logos Capital, OrbiMed.

Collective explained in 2 minutes

Learn how Collective's solutions enable you to manage your risk and maximize your wealth

Unlock My Liquidity